Chiesi Group to acquire KalVista Pharmaceuticals, expanding its global rare disease portfolio

Chiesi Group, an international research-focused biopharmaceutical group, and KalVista Pharmaceuticals, Inc., announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s a...